MagicMed Industries has inked an amalgamation agreement with medical CBD biotech Enveric Biosciences (NASDAQ: ENVB). Psilocybin Alpha understands MagicMed will be acquired by the listed company via an all-stock transaction. Upon closing of the transaction, MagicMed’s CEO Dr. Joseph Tucker would be appointed CEO of Enveric Biosciences; Enveric’s current CEO, David Johnson…


Previous articlePsychedelic Bulletin: CB Therapeutics’ Biosynthesis Patent; MindMed to Explore Mescaline; BBC Documentary Highlights Psilocybin
Next articleMindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System